Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics reports positive VK2735 maintenance study topline results

Positive Impact 4 of 5 other Written later

Viking Therapeutics reported positive topline results from the maintenance phase of its VK2735 study, in which patients moved to every-other-week or monthly dosing maintained up to 97% and up to 90% of their weight loss, respectively. The company also reported GI-related adverse event rates similar to placebo, and the filing presents no financial measures for the period.

Key points

  • Every-other-week dosing maintained up to 97% of Week 21 weight loss versus 61% for placebo (p<0.0001).
  • Monthly dosing maintained up to 90% of Week 21 weight loss versus 61% for placebo (p=0.0002).
  • Induction phase: weight loss of approximately 16% to 19% after 21 weeks of weekly dosing versus approximately 0% for placebo.
  • Management conference call scheduled for 8:00 a.m. ET on September 22, 2026.

The filing

CompanyViking Therapeutics, Inc. (VKTX)
Form8-K, current report
Filed with the SECSep 22, 2026, 7:06 AM ET
Accession number0001193125-26-397219

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.